Discover Precision: Join ZEISS at the Control Fair in Stuttgart

May 6-9, 2025 in Stuttgart. Hall 9, Booth 9309.

Sustainability at Festo

On the Way to the Net Zero Era - New Sustainability Report published

Gothenburg, the city of life science – We are ‘Little Boston’

Western Sweden is investing in life science within everything from advanced therapeutic drugs to femtech. At the same time, stakeholders are looking to other in...

Developing rapid diagnostics for sepsis – “Every hour counts”

Finding the right antibiotic in the right dose – with an ultra-fast analysis method. Gradientech's product solution is currently used in routine diagnostics at ...

ZEISS Lightfield 4D for instant volumetric high-speed imaging

Capturing physiological and neuronal processes in 3D.

Spatial Biology Studies in Lung Tissue using Spectral Microscopy

Spectral imaging with the ZEISS LSM 980 laser scanning confocal enables more complex studies of cell-cell interactions and locations in immunology research.

Festo Expands its Portfolio with Multilayer Manifolds

Manufacturers of medical and laboratory equipment now receive solutions from a single source

Life science trends 2025 – Part 1 obesity drugs

More obesity drugs are being launched this year following Novo Nordisk and Eli Lilly's previous successes with GLP-1 drugs. But the next big breakthrough in obe...

ZEISS presents the "Quality Innovation Days"

The digital event for metrology and software.

Korbinian Löbmann leads scientific meeting on drug formulation: High activity in the field

Korbinian Löbmann has moderated New Updates in Drug Formulation & Bioavailability several times before. Now he is once again taking on the scientific meeting. L...

Metabolon

Career coach on salaries: “There is no right or wrong”

What is a reasonable salary for my job? It's a question we all ask ourselves. But how important is a higher salary really? Career coach Tina Persson believes th...

Nytt svenskt alzheimerläkemedel i fas III – ”Vi angriper det största problemet”

En ny typ av alzheimerbehandling är på väg att utvecklas av svenska forskare. ”Det här lät först för bra för att vara sant, men efter tio års arbete har vi vant...

Study: Chat GPT is more empathetic than doctors

The AI tool Chat GPT is not only more accurate when it comes to answering patient questions – the chatbot is also perceived as almost 10 times more empathetic t...

Ancient DNA provides new insights – “The immune system lost its job”

Ancient bone remains from our ancestors have provided new insights into the prevalence of multiple sclerosis. By looking back in time, researchers can provide a...

The Future of Swedish & Danish Life Science (2026)

The impact of the recession on the Swedish medtech sector

We need health care regardless of whether the economy is good or bad, but the current recession also affects the Medtech sector.

The business coach: “We need to learn from our mistakes”

The past year has been challenging for many biotech companies, with several comapanies facing financial stress and bankruptcy. To understand how entrepreneurs c...

“You discover one thing – and then 10 new questions arise”

COVID-19, diabetes, heart disease, and the impact of dog ownership on humans are just some of multitasker Tove Fall’s areas of research. However, her current fo...

Revealing the secrets of a part

CT inspection in automation technology at Festo.

New cell therapy raises hope for curing type 1 diabetes – "Never succeeded before"

For the first time, a patient with type 1 diabetes has undergone an islet transplantation using genetically modified insulin-producing cells that do not require...

Hennes tablett ska bli en ny typ av fetmabehandling

Obesitas och diabetes är huvudmålen för en ny tablettbehandling under utveckling av Malmöbolaget Pila Pharma. Företagets mål: att ta upp kampen med de miljardsä...

BioArctic moves forward with its candidate for Parkinson’s

BioArctic announces positive early phase study results for its drug candidate for Parkinson’s disease.

New drug to simplify treatment of hemophilia

A new type of treatment for hemophilia, which only needs to be administered every two months, has been approved by the U.S. Food and Drug Administration (FDA).